Intra-cellular therapies reports second quarter 2022 financial results and provides corporate update

Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase

ITCI Ratings Summary

ITCI Quant Ranking